Related Experiment Video
Updated: Dec 10, 2025

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
Published on: October 14, 2015
Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
Roshni D Kalachand1, Ciaran O'Riain2, Sinead Toomey1
1Medical Oncology Group, Department of Molecular Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland.
Objective:
The therapeutic benefits of poly(ADP-ribose) polymerase inhibitors highlight the need to evaluate BRCA1/2 defects in tubal/ovarian cancer (OC). We sought to determine the pattern and disease characteristics associated with tumor BRCA1/2 mutations and BRCA1 methylation in women with OC.
Methods:
We obtained 111 OC specimens from 2 university hospitals and assessed BRCA1/2 mutations and BRCA1 methylation in tumor DNA. The frequency and pattern of BRCA1/2 defects were examined. Associations between patient/disease characteristics and BRCA1/2 defects were ascertained (Fisher's exact test). Platinum-free interval (PFI), progression-free survival (PFS), and overall survival (OS) based on the underlying BRCA1/2 defect were determined (Kaplan-Meier analysis [log-rank test]).
Results:
We observed a BRCA1/2 dysfunction rate of 40% (28/70) in high-grade serous tubal/ovarian cancer (HGSC), including 14.3% BRCA1 methylation (n=10), 7.1% BRCA1 mutation (n=5), and 18.6% BRCA2 mutation (n=13). Defects in BRCA1/2 genes were associated with stage III/IV HGSC (BRCA1 methylation: P=0.005 [stage III/IV] and P=0.004 [HGSC]; BRCA1/2 mutation: P=0.03 [stage III/IV] and P<0.001 [HGSC]). Patients with BRCA1/2-mutated cancers showed improved OS (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.43-0.99; P=0.045) and a trend toward improved PFI (HR, 0.48; 95% CI, 0.22-1.06; P=0.07) and PFS (HR, 0.72; 95% CI, 0.51-1.03; P=0.07). No survival differences were observed between BRCA1-methylated and BRCA1/2 wild-type non-BRCA1-methylated cancers.
Conclusion:
We observed a high tumor BRCA1/2 dysfunction rate in HGSC with a unique predominance of BRCA2 over BRCA1 mutations. While BRCA1/2 mutations conferred survival benefits in OC, no such association was observed with BRCA1 methylation.
Insights
Ovarian cancer (OC) patients with BRCA1/2 mutations show improved survival, particularly in high-grade serous types. BRCA1 methylation, however, did not correlate with survival benefits in this study.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Poly(ADP-ribose) polymerase (PARP) inhibitors offer therapeutic benefits in ovarian cancer (OC).
- Evaluating BRCA1/2 gene defects is crucial for understanding OC treatment responses.
- Tumor BRCA1/2 mutations and BRCA1 methylation patterns are key determinants in OC.
Purpose of the Study:
- To determine the frequency and characteristics of BRCA1/2 defects in OC.
- To investigate the association between BRCA1/2 defects and disease parameters.
- To assess the impact of BRCA1/2 defects on patient survival outcomes.
Main Methods:
- Analysis of 111 OC tumor specimens for BRCA1/2 mutations and BRCA1 methylation.
- Examination of BRCA1/2 defect patterns and frequencies.
- Statistical analysis (Fisher's exact test, Kaplan-Meier) to correlate defects with clinical characteristics and survival (PFI, PFS, OS).
Main Results:
- A 40% BRCA1/2 dysfunction rate was observed in high-grade serous ovarian cancer (HGSC).
- BRCA1/2 defects were significantly associated with advanced stage III/IV HGSC.
- BRCA1/2 mutations correlated with improved overall survival (OS) and trends towards better progression-free survival (PFS) and platinum-free interval (PFI).
Conclusions:
- High tumor BRCA1/2 dysfunction rates, with a notable prevalence of BRCA2 mutations, are present in HGSC.
- BRCA1/2 mutations are linked to survival advantages in OC patients.
- BRCA1 methylation did not demonstrate a significant association with improved survival outcomes in OC.
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Oogenesis
Cancer
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Cancer Prevention
Some...

